• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press Releases
  • Suppliers
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • Our Company
    • About Us
    • Responsibility
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel®
    • ATA188
    • ATA3219
    • ATA2271/ATA3271
  • Patients & Families
    • Our Mission
    • Stories of Strength
    • About EBV
    • PTLD
    • Multiple Sclerosis
    • Clinical Studies
    • Expanded Access
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Careers Home
    • Career Areas
    • Job Search
  • Contact
  • Medical Professionals
  • Press Releases
  • Suppliers
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023

Feb 06, 2023 8:00am EST

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 03, 2023 4:01pm EST

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2023 4:01pm EST

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 04, 2023 4:01pm EST

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

Dec 20, 2022 4:33pm EST

Atara Biotherapeutics Announces Changes to Its Board of Directors

Dec 19, 2022 8:00am EST

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Dec 19, 2022 7:00am EST

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 15, 2022 4:01pm EST

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting

Dec 12, 2022 10:00am EST

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 02, 2022 4:01pm EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...31
Next
  • Email Alerts
  • Contacts
  • RSS News Feed

Footer

  • LinkedIn
  • Twitter
© 2023 Atara Biotherapeutics, Inc. All rights reserved.
  • Privacy Policy
  • Terms of Use
  • Sitemap